Showing results (61-70 of 127) with videos related to
Sort By:
Pageof 13
Blood|September 17, 2010
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomesEbenezer David, Jonathan L Kaufman, Christopher R Flowers, et al.Cancer Biology & Therapy|June 2, 2016
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myelomaKatelyn G Ponder, Shannon M Matulis, Sadae Hitosugi, et al.Blood|June 11, 2011
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cellsAlejo A Morales, Metin Kurtoglu, Shannon M Matulis, et al.Leukemia & Lymphoma|September 28, 2022
Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapySusan Bal, Timothy M Schmidt, Luciano J Costa, et al.Blood Cancer Journal|September 13, 2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patientsNisha S Joseph, Jonathan L Kaufman, Vilas A Gupta, et al.Clinical Lymphoma, Myeloma & Leukemia|April 27, 2019
Immunotherapy in Multiple Myeloma: Accelerating on the Path to the PatientIrene Ghobrial, Calixto Hernández Cruz, Alfred Garfall, et al.Blood Advances|November 8, 2019
Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myelomaYu-Hsiu T Lin, Gregory P Way, Benjamin G Barwick, et al.Blood|September 16, 2011
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitorsPaola Neri, Li Ren, Kathy Gratton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2020
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple MyelomaNisha S Joseph, Jonathan L Kaufman, Madhav V Dhodapkar, et al.Blood|May 1, 2014
CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myelomaMegan E Murray, Catherine M Gavile, Jayakumar R Nair, et al.Pageof 13